 I. Determine the complete and partial response rates and time to treatment failure in patients with relapsed or refractory anaplastic large cell lymphoma, mantle cell lymphoma, or classical Hodgkins lymphoma treated with 17-N-allylamino-17-demethoxygeldanamycin 17-AAG. 